Literature DB >> 29102779

Sialic acid and anti-ganglioside antibody levels in children with autism spectrum disorders.

Xiaolei Yang1, Shuang Liang1, Lin Wang1, Panpan Han1, Xitao Jiang1, Jianli Wang2, Yanqiu Hao3, Lijie Wu4.   

Abstract

BACKGROUND: Autism spectrum disorders (ASD) may result from a combination of genetic and environmental factors, and impact neurological functions and behaviors. Sialic acid (SA) is an indispensable nutrient for early brain development, and its polymer polySia (PSA) can modify neural cell adhesion molecules (NCAM), thereby indirectly mediating neuronal outgrowth, synaptic connectivity and memory formation. To investigate the association between SA and ASD, we conducted a case-control study.
METHODS: The study sample included 82 autistic children and 60 healthy children. We measured the levels of plasma SA and serum anti-gangliosides M1 antibodies (anti-GM1 antibodies) in the ASD and control groups. We also examined the severity of autistic children.
RESULTS: The level of plasma SA in the control group was significantly higher than that in the ASD group (p < .01). Autistic children had higher positive rates of anti-GM1 antibodies (37.8%) than controls (21.67%, P = .04). However, there was no correlation between autistic severity and the levels of SA. SA may be as a biomarker for diagnosis of ASD with a positive predictive value of 84.42%, a negative predictive value of 73.85% and an area under the ROC curve value of 0.858.
CONCLUSIONS: These results indicate that SA and anti-GM1 antibodies are associated with ASD. Our data suggested that future studies to explore the function of SA in the etiology of ASD may be needed.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti-ganglioside antibodies; Autism spectrum disorders; Sialic acid

Mesh:

Substances:

Year:  2017        PMID: 29102779     DOI: 10.1016/j.brainres.2017.10.027

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  7 in total

1.  Levels of Salivary Sialic Acid in Children with Autism Spectrum Disorder; Could It Be Related to Stereotypes and Hyperactivity?

Authors:  Esra Demirci; Yunus Guler; Sevgi Ozmen; Mehmet Canpolat; Sefer Kumandas
Journal:  Clin Psychopharmacol Neurosci       Date:  2019-08-31       Impact factor: 2.582

2.  The association between ST8SIA2 gene and behavioral phenotypes in children with autism spectrum disorder.

Authors:  Xiaolei Yang; Lin Li; Xuejiao Chai; Jicheng Liu
Journal:  Front Behav Neurosci       Date:  2022-07-25       Impact factor: 3.617

3.  Carbon monoxide (CO) correlates with symptom severity, autoimmunity, and responses to probiotics treatment in a cohort of children with autism spectrum disorder (ASD): a post-hoc analysis of a randomized controlled trial.

Authors:  Hannah Tayla Sherman; Kevin Liu; Kenneth Kwong; Suk-Tak Chan; Alice Chukun Li; Xue-Jun Kong
Journal:  BMC Psychiatry       Date:  2022-08-08       Impact factor: 4.144

4.  Sialic acid biosensing by post-printing modification of PEDOT:PSS with pyridylboronic acid.

Authors:  Hideki Fujisaki; Akira Matsumoto; Yuji Miyahara; Tatsuro Goda
Journal:  Sci Technol Adv Mater       Date:  2022-09-16       Impact factor: 7.821

5.  Correlation Between Sialidase NEU1 mRNA Expression Changes in Autism Spectrum Disorder.

Authors:  Haiqing Zhang; Yuhang Gu; Wenxiang He; Fengyi Kuo; Yiran Zhang; Duan Wang; Li He; Ying Yang; Hepeng Wang; Yanni Chen
Journal:  Front Psychiatry       Date:  2022-06-09       Impact factor: 5.435

6.  The level of GNE and its relationship with behavioral phenotypes in children with autism spectrum disorder.

Authors:  Xiaolei Yang; Hongjie Li; Jie Ge; Hong Chao; Gang Li; Zhongguang Zhou; Jicheng Liu
Journal:  Medicine (Baltimore)       Date:  2020-07-10       Impact factor: 1.817

Review 7.  Antigenic Targets of Patient and Maternal Autoantibodies in Autism Spectrum Disorder.

Authors:  Rut Mazón-Cabrera; Patrick Vandormael; Veerle Somers
Journal:  Front Immunol       Date:  2019-07-19       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.